A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...

In the Phase II STARLIGHT trial, MCO-010 gene therapy improved visual acuity in Stargardt disease patients, with some achieving early and sustained gains and no serious adverse events, paving the way ...

The trial’s first patient has been treated to assess the BREATHE Airway Scaffold, which was developed to enhance breathing and daily functioning in patients with severe emphysema.

Michael Weis, SM, is principal of Michael B. Weis Consultancy, P.O. Box 414, Ringoes, NJ 08551, (609) 466-1261, fax (609) 466-9353, email: [email protected].